ReviewFrontiers in microbiology2026
Oncolytic viruses in lung cancer: mechanisms of action and research progress.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, posing a profound public health challenge. Current primary therapeutic modalities-surgical resection, radiotherapy, and chemotherapy-often exhibit limited efficacy, accompanied by frequent adverse events and treatment resistance. Oncolytic viruses (OVs), an emerging class of anti-cancer therapeutics, can infect and lyse cancer cells while their effects on normal tissues are generally limited. Leveraging OVs in lung cancer therapy holds substantial promise for improving patient survival outcomes. This review comprehensively examines the multifaceted anti-cancer mechanisms of OVs, including induction of apoptosis, immunogenic cell death, and neoantigen presentation. Additionally, it explores promising combinatorial strategies, such as OV-based immunotherapy and targeted therapies. By synthesizing current evidence, this review aims to inform the optimization of OV-based therapeutic regimens for lung cancer, ultimately enhancing patient survival and quality of life while addressing limitations of conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.